Samuel Broder - 17 May 2023 Form 4 Insider Report for Orion Biotech Opportunities Corp.

Role: Director
Signature: /s/ Marcello Liguori, as attorney in fact for Samuel Broder
Issuer symbol: N/A
Transactions as of: 17 May 2023
Net transactions value: $0
Form type: 4
Filing time: 18 May 2023, 16:05:11 UTC
Previous filing: 14 Jun 2022
Next filing: 12 Jul 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ORIA	Class B ordinary shares	Disposed to Issuer	$0	-40,000	-100%	$0.000000^*	0	17 May 2023	Class A ordinary shares	40,000		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Samuel Broder is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	On April 21, 2023, the Issuer announced that it will not consummate an initial business combination within the time period required. Pursuant to the Issuer's Amended and Restated Memorandum and Articles of Association (the "Articles") and in connection with the winding up of the Issuer, the Class B ordinary shares, par value $0.0001, held by the Reporting Person were surrendered for no compensation on May 17, 2023.

Content

On April 21, 2023, the Issuer announced that it will not consummate an initial business combination within the time period required. Pursuant to the Issuer's Amended and Restated Memorandum and Articles of Association (the "Articles") and in connection with the winding up of the Issuer, the Class B ordinary shares, par value $0.0001, held by the Reporting Person were surrendered for no compensation on May 17, 2023.

Remarks:

After giving effect to the Issuer's delisting and deregistration, the Reporting Person will no longer be subject to Section 16 reporting obligations.